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Abstract
Objective To evaluate the association between migraine and cognitive
decline among women.
Design Prospective cohort study.
Setting Women’s Health Study, United States.
Participants 6349 women aged 65 or older enrolled in the Women’s
Health Study who provided information about migraine status at baseline
and participated in cognitive testing during follow-up. Participants were
classified into four groups: no history of migraine, migraine with aura,
migraine without aura, and past history of migraine (reports of migraine
history but no migraine in the year prior to baseline).
Main outcome measures Cognitive testing was carried out at two year
intervals up to three times using the telephone interview for cognitive
status, immediate and delayed recall trials of the east Boston memory
test, delayed recall trial of the telephone interview for cognitive status
10 word list, and a category fluency test. All tests were combined into a
global cognitive score, and tests assessing verbal memory were
combined to create a verbal memory score.
Results Of the 6349 women, 853 (13.4%) reported any migraine; of
these, 195 (22.9%) reported migraine with aura, 248 (29.1%) migraine
without aura, and 410 (48.1%) a past history of migraine. Compared
with women with no history of migraine, those who experienced migraine
with or without aura or had a past history of migraine did not have
significantly different rates of cognitive decline in any of the cognitive
scores: values for the rate of change of the global cognitive score
between baseline and the last observation ranged from −0.01 (SE 0.04)
for past history of migraine to 0.08 (SE 0.04) for migraine with aura when
compared with women without any history of migraine. Women who
experienced migraine were also not at increased risk of substantial
cognitive decline (worst 10% of the distribution of decline). When
compared with women without a history of migraine, the relative risks
for the global score ranged from 0.77 (95% confidence interval 0.46 to
1.28) for women with migraine without aura to 1.17 (0.84 to 1.63) for
women with a past history of migraine.
Conclusion In this prospective cohort of women, migraine status was
not associated with faster rates of cognitive decline.
Introduction
Migraine is a chronic-intermittent primary headache disorder
thataffectsabout20%ofthefemalepopulation.
1Uptoonethird
of those with migraine experience aura (that is, transient
neurologysymptomsmainlyofthevisualfield)beforeorduring
a migraine attack. Besides the headache, migraine is believed
to usually be a benign condition. However, previous studies
have linked migraine, especially migraine with aura, to an
increasedriskofischaemicstroke.
2Inadditiontoincreasingthe
risk of stroke, migraine has also been associated with an
increased prevalence of clinically silent brain lesions.
3-5 In the
general population, silent brain lesions have been shown to be
a risk factor for dementia and cognitive decline,
6 leading to
speculation that migraine may be a progressive brain disorder.
7
Determining if there is an association between migraine and
cognitive decline among women is important because women
aremorelikelythanmentoexperiencemigraines
1andalsohave
a higher prevalence of dementia.
8 If an association between
migraine and cognitive decline does exist, preventing the onset
of migraines may be one way to slow the progression of
cognitive decline. Additionally, interventions aimed at
preserving cognitive function could be targeted to women who
experience migraine.
Althoughseveralcrosssectionalstudies
9-19andafewprospective
studies
20-22haveexaminedtheassociationbetweenmigraineand
cognitive decline, many were small or were unable to stratify
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Research
RESEARCHthe association between migraine and cognitive decline by aura
status. Using data from the Women’s Health Study, we
examined the association between migraine subtypes and
cognitive decline during four years of follow-up.
Methods
The Women’s Health Study was a randomised, placebo
controlled clinical trial designed to test the effects of low dose
aspirin and vitamin E in the primary prevention of
cardiovasculardiseaseandcancer.Thedesignandresultsofthe
study have been reported previously.
23-25 Briefly, at baseline
(1992-95), 39 876 US female health professionals age 45 or
older without a history of cardiovascular disease, cancer, or
other major illnesses were enrolled. The clinical trial ended in
March 2004, and the women are currently being followed in an
observational study.
In 1998, a cognitive subcohort of women participating in the
Women’s Health Study was started.
26 27 Women were eligible
to participate if they were aged 65 or older. Of the 7175 women
eligible to participate, 6377 completed the initial cognitive
assessment. Two additional follow-up assessments were done,
each about two years apart. Of those who completed the initial
assessment, 5845 (91.7%) completed at least one follow-up
assessmentand5073(79.5%)completedallassessments.About
8% of participants did not complete any follow-up assessments
owing to death (2%), being unreachable (1%), or refusal (5%).
Assessment of migraine
On the baseline questionnaire we asked the women “Have you
ever had migraine headaches?” and “In the past year, have you
had migraine headaches?” We also asked the women who
reported experiencing migraine headaches within the past year
aboutthecharacteristicsoftheirattacks,includingthepresence
ofauraoranyindicationthatamigrainewascoming.Usingthe
women’s responses to these questions, we divided them into
fourcategories:nomigrainehistory,migrainewithaura(women
who indicated experiencing migraine within the year before
baselineandwhoreportedthepresenceofauraoranyindication
that a migraine was coming), migraine without aura, and a past
historyofmigraine(womenwhoreportedeverhavingmigraine
headache but not experiencing migraine headache within the
year before baseline). Previous validation studies in the
Women’s Health Study have shown good agreement between
self reported migraine and the International Classification of
Headache Disorders I and II.
28 29 For this analysis we excluded
the 28 women who did not provide information on migraine
status at baseline. The figure⇓ shows the number of women
included and excluded at each stage of the design.
Assessment of outcomes
Interviewers blinded to the participant’s migraine status
administered the telephone cognitive assessment. The
assessment was composed of five separate tests: telephone
interview for cognitive status, immediate and delayed recall
trials of the east Boston memory test, delayed recall trial of the
telephone interview for cognitive status 10 word list, and a
category fluency task. The telephone interview for cognitive
status assesses global cognitive function and is a telephone
adaptationofthemini-mentalstateexamination.
30Scoresrange
from0to41points,andthetestisshowntohavehighreliability
andvalidityformeasuringcognitivefunction.
31TheeastBoston
memory test assesses verbal memory with scores ranging from
0 to 12 points.
32 The delayed recall of the telephone interview
for cognitive status 10 word list also assesses verbal memory.
The category fluency test assesses language and executive
functioning
26 33 by asking women to name as many animals as
possibleinoneminute.Thevalidityofthetelephoneassessment
compared with face to face interviews has been shown in
previous studies (r=0.81 comparing our brief telephone
administered cognitive assessment with face to face interviews
composed of 21 tests).
26 34
To create a global cognitive score we averaged z scores for
performance on each of the five tests. For the 0.4% of
participants who did not complete all five tests we used the
meanofthezscoresofthecompletedtests.Wecreatedaverbal
memory composite score by averaging the z scores of the
immediate and delayed recalls of both the east Boston memory
test and the telephone interview for cognitive status 10 word
list. Both of these composite scores have been used in previous
studies in the Women’s Health Study.
26 27 33 34 Finally, we also
examined separately scores on the telephone interview for
cognitive status as an additional measure of global cognition
and scores on the category fluency task as executive function
is particularly affected by clinical or subclinical stroke.
Statistical analysis
We calculated means for continuous baseline characteristics
andfrequenciesforcategoricalbaselinecharacteristics.Ateach
cognitive assessment we used repeated measures analyses to
examine mean performance. We adjusted for several potential
confounders,asmeasuredatbaseline:age(continuous),smoking
status(never,former,current),alcoholconsumption(≤3drinks
per month, 1-6 drinks per week, ≥1 drinks per day), body mass
index (<25, 25-29.9, ≥30 kg/m
2), educational attainment (less
thanabachelorsdegreesversusbachelorsdegreeorabove),use
of postmenopausal hormones (never, current, or past), history
of high cholesterol levels (yes or no), treatment for high
cholesterol levels (yes or no), history of hypertension (yes or
no),treatmentforhypertension(yesorno),diabetes(yesorno),
and history of oral contraceptive use (yes or no).
To examine change in cognitive functioning over time we used
general linear models of response profiles. Similar to previous
studies done using data from the Women’s Health Study,
26 27 33
we modelled time nominally rather than linearly (since there
was not a linear relation between time and cognitive
performance) and modelled the effect of migraine status over
time(thejointeffectsofmigraineandtime)byusinginteraction
terms between migraine status and time. All models were fitted
using maximum likelihood and accounted for the longitudinal
correlation within participants by using an unstructured
covariancematrix.Wecarriedoutageandmultivariableadjusted
analyses. The multivariable analysis adjusted for the same
potential confounders as the repeated measures analysis of
means with the exception of excluding treatment for high
cholesterol levels for the global score and category fluency
outcomes due to problems with model convergence. We also
testedforeffectmodificationbyage(dichotomisedatthemedian
ageof75years),historyofhypertension,cardiovasculardisease
(all incident occurrences from baseline to the end of the
cognitive substudy), baseline score for the global score, verbal
score, telephone interview for cognitive status, and category
fluency score (dichotomised at the median), perceived change
in memory (worse versus no change or improvement), and
educational attainment. The testing was done by including a
threewayinteractiontermforeachvariablewithmigrainestatus
and time in separate age adjusted models.
We assigned women with missing information on body mass
index (n=149) to a separate category. For other covariates, the
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RESEARCHnumber of women with missing information was small (<100
for each variable), so we assigned them to the never/rarely or
no use categories or, in the case of education, we used
information on years of education to impute their highest
educational attainment.
We carried out additional analyses using logistic regression to
determine if migraine increased the risk of “substantial”
cognitive decline. Substantial cognitive decline was defined as
the worst 10% of the distribution of decline from the initial to
the final cognitive assessment of the whole study cohort. We
adjusted for all variables included in our previous analyses of
mean scores and also adjusted for the time between entry into
the Women’s Health Study and third cognitive assessments.
All models were fit using SAS 9.1. All probability values were
two tailed, and we considered P<0.05 to be statistically
significant.
Results
Of the 6349 women, 853 (13.4%) reported any migraine; of
these, 195 (22.9%) reported migraine with aura, 248 (29.1%)
migraine without aura, and 410 (48.1%) a past history of
migraine. Table 1⇓ shows the baseline characteristics of the
participating women. Women who experienced migraine with
aura were less likely to consume alcohol than women in the
other migraine categories. Women who reported a past history
ofmigrainehadlesseducationthanwomenwithoutanyhistory
of migraine, migraine with aura, or migraine without aura.
Women with no history of migraine were more likely to have
diabetes. Women with migraine without aura were the least
likely to exercise.
The mean follow-up time for the cognitive substudy was 3.4
years. Table 2⇓ shows the average test scores at each cognitive
assessment by migraine status adjusted for potential
confounders. The global scores, verbal scores, or telephone
interview for cognitive status scores did not differ significantly
among the migraine categories. For the category fluency test,
the scores differed significantly among the migraine groups at
the second and third cognitive testing. Overall, cognitive
performance seemed to be similar or even slightly better for
women in the migraine groups than for women with no history
of migraine.
Table3⇓presentstheresultsfromageandmultivariableadjusted
longitudinal analyses. All of the interaction terms between
migraine categories and time were close to the null and
non-significant, providing no evidence of differences in rates
of cognitive decline for those with no history of migraine
compared with women who experienced migraine with or
without aura or had a past history of migraine.
The risk of substantial cognitive decline in women who
experienced migraine with or without aura or had a past history
of migraine was not increased (table 4⇓) compared with those
with no history of migraine. In secondary analyses, we found
no evidence of significant effect modification by history of
hypertension, baseline score, perceived change in memory, or
educational attainment. Statistically significant effect
modification by age (less than or higher than the median of 75
years) was observed for the telephone interview for cognitive
status (P=0.02). This result seemed to be driven by a greater
rate of cognitive decline at the third time point among those
with a past history of migraine who were older than the median
age (β coefficient −0.85) compared with those who were
youngerthanthemedianage(βcoefficient0.07).Nostatistically
significant effect modification by median age was observed for
the other cognitive outcomes. Statistically significant effect
modification by cardiovascular disease was observed on the
categoryfluencytest(P=0.01).Amongwomenwhoexperienced
migrainewithaura,thosewhoalsoexperiencedacardiovascular
event had greater rates of decline (β coefficient −2.76 at the
secondtimepointandβcoefficient−2.43atthethirdtimepoint)
than those who did not experience a cardiovascular event (β
coefficient−0.50atthesecondtimepointandβcoefficient0.70
at the third time point). No statistically significant effect
modificationbycardiovasculareventwasobservedfortheother
cognitive outcomes.
Discussion
Resultsfromthislarge,prospectivecohortstudyamongwomen
provide no evidence that migraine is associated with greater
rates of cognitive decline when compared with women without
a history of migraine. This result did not differ according to
migraine aura status or past history of migraine. We also did
not observe meaningful effect modification of this lack of
association for most of our migraine groups. We did observe
some effect modification by age for those with a past history of
migraine,suggestingthatolderwomenhadfasterratesofdecline
on the telephone interview for cognitive status than younger
women. Additionally, among women with migraine with aura,
those who experienced a cardiovascular event had faster rates
of decline on the category fluency test than those without a
cardiovascular event.
Comparisons with other studies
Cross sectional studies have shown mixed results on the
association between migraine status and lower cognitive
functioning. Some studies have shown no differences among
thosewithandwithoutmigraine,
9-14whereasothershaveshown
evidence of worse cognitive functioning among those who
experiencemigraine.
15-19However,owingtotheircrosssectional
nature, none of these studies could examine the association
between migraine and cognitive decline, a more meaningful
outcome than cognition at any single time point.
The prospective studies on the association between migraine
andcognitivedeclineamongadultshavenotfoundgreaterrates
of cognitive decline among people with migraine compared
with people without migraine.
20-22 The Baltimore cohort of the
National Institute of Health Mental Health Epidemiology
CatchmentAreastudyfoundthatalthoughadultswithmigraine
overall and those with migraine with aura who were aged 50 or
older at baseline showed lower baseline scores on tests of
delayedandimmediaterecall,theyactuallyshowedlessdecline
in those tests over time compared with people aged 50 or older
at baseline who did not have migraines. Rates of decline did
not differ between people aged less than 50 at baseline with
migraineandthosewithout.
21TheMaastrichtAgeingStudydid
not find differences between people with and without migraine
indeclineonthemini-mentalstateexamination,immediateand
delayedrecalloftestswith15wordlists,orothertestsforsimple
and complex speed.
20 Finally, the Epidemiology of Vascular
Ageing Study found no evidence of greater cognitive decline
among people who experienced migraine on any of a wide
variety of cognitive tests. For the Wechsler adult intelligence
scale-revised, there was evidence that people who experienced
migraine declined less over time than those with no history of
severeheadache.Therewasalsolittleevidencethatthepresence
of white matter hyperintensities or brain infarction modified
the association between migraine and cognitive decline.
22
In the present study we also found little evidence that cognitive
functionamongthosewhoexperiencedmigrainedeclinedmore
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RESEARCHthan those without a history of migraine. Since this study was
much larger than previous studies, we were able to examine the
impact of migraine with aura, migraine without aura, and past
historyofmigraine.Examiningtheassociationbetweenmigraine
and cognitive decline by aura status is important because
migraine with aura has been linked to more deleterious effects
on the brain, particularly ischaemic vascular changes.
4
Additionally,wewereabletocarryoutothersubgroupanalyses
by age or the presence of cardiovascular disease, which could
not be done in previous studies.
Strengths and limitations of the study
The strengths of this study include its large prospective design,
standardised assessment of migraine status, information on
migrainewithandwithoutaura,andtheavailabilityofvalidated
cognitive function measures
26 34 at multiple time points, which
allowed us to examine change in cognitive function over time.
Several limitations should be considered when interpreting our
results.Ourcohortwascomposedofwomenaged65andolder,
mostly white, female health professionals, which might limit
the ability to generalise our results to other cohorts. However,
we do not believe that the biological mechanisms linking
migrainewithcognitivedeclinewouldbedifferentinourcohort
compared with other populations. Since migraine was self
reported, women may incorrectly report their migraine status.
However, all participants were health professionals who are
known to report health information accurately. Furthermore,
validation studies have shown good agreement between self
reported migraine and the International Classification of
Headache Disorders I and II.
28 29 Although our study was not
able to examine the impact of migraine on cognitive decline
among men, potential effects of migraine on subsequent
conditions, such as cognitive decline, are of particular interest
inwomenbecauseofthelongerlifeexpectancyamongwomen.
Overall we did not observe a large amount of cognitive decline
among our participants, possibly because of the age of the
participants and the short follow-up period. Additionally,
although the telephone interview for cognitive status does not
seem to show a ceiling effect as strong as that seen for the
mini-mental state examination,
35 it is possible that the women
in our cohort may not have been declining enough for our
“global score” to detect changes in cognitive status. However,
other studies using this cohort have detected risk factors for
cognitive decline, such as type 2 diabetes, longer duration of
diabetes, educational status, and income,
33 36 which suggests
that our study period was long enough to observe a meaningful
cognitive decline. Given that the Baltimore Epidemiology
Catchment Area Study had a much longer period of follow-up
than our study (1993 to 2005) and also did not find evidence of
worse decline among people who experience migraine further
helps to ameliorate concerns that the women in our study may
not have been followed for long enough to detect decline.
Cognitive assessment was done several years after the start of
the trial, so there could be possible bias due to loss to follow-up
ifwomenwhoexperiencedmigraineweremorelikelytobelost
to follow-up before the start of cognitive testing and had lower
cognitivescoresthanwomenremaininginthecohort.However,
onlyasmallpercentageofwomen(1.5%)werelosttofollow-up
between baseline and cognitive assessment
27 so any bias would
be relatively small. We did have some loss to follow-up over
the course of our study, but the percentage of women lost to
follow-up in the migraine categories was similar to that among
the women with no history of migraine. Finally, although this
study is larger than many previous studies, we may not have
had enough participants in our migraine categories to detect
small differences in cognitive decline among our groups.
Clinical implications
Results of this study do not suggest that women with migraine
with or without aura or with a past history of migraine have an
increased risk of cognitive decline. Based on the results from
this study and from previous studies using a wide variety of
cognitive tests and various approaches to assessing migraine
status,migrainedoesnotseemtoleadtofunctionalimpairments
of the brain. Based on these results, patients with migraine and
theirtreatingdoctorsshouldbereassuredthatmigrainemaynot
have long term consequences on cognitive function. We did
observe greater rates of cognitive decline in the subgroup of
women who experience migraine with aura and had a history
ofcardiovasculardiseasecomparedwithwomenwhoexperience
migraine with aura and did not have history of cardiovascular
disease. However, because of the multiple subgroup analyses,
thisresultshouldbeinterpretedwithcautionandfurtherresearch
iswarrantedtodeterminewhethertheinterplayofmigraineand
cardiovascular disease leads to faster cognitive decline, and
whether preventive strategies can be applied.
Unanswered questions and future research
Migraineisacomplexdiseaseandhasbeenlinkedwithvarious
comorbidities,suchasstrokeandothervasculardiseaseevents.
However,themechanismsunderlyingtheseassociationsarenot
fullyunderstood.Evaluatingtheinterrelationsbetweenmigraine
and other diseases remains an important research target to
establish strategies to positively influence the course of disease
and to optimise treatment strategies.
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RESEARCHTables
Table 1| Baseline characteristics of 6349 women according to migraine status. Values are numbers (percentages) of women unless stated
otherwise
Past history of migraine
(n=410)
Migraine
No migraine history (n=5496) Characteristic Without aura (n=248) With aura (n=195)
66.4 (4.13) 65.3 (3.6) 65.9 (3.9) 66.3 (4.1) Mean (SD) age at study randomization (years)
72.1 (4.1) 71.0 (3.5) 71.6 (3.9) 71.9 (4.1) Mean age (SD) at baseline cognitive interview
(years)
Body mass index:
213 (52.0) 127 (51.2) 99 (50.8) 2670 (48.6) <25
136 (33.2) 83 (33.5) 70 (35.9) 1860 (33.8) 25-29.9
54 (13.2) 34 (13.7) 21 (10.8) 833 (15.2) ≥30
192 (46.8) 91 (36.7) 75 (38.5) 2188 (39.8) History of hypertension
100 (24.4) 56 (22.6) 40 (20.5) 1230 (22.4) Antihypertensive drug use
117 (43.2) 110 (44.4) 98 (50.3) 2346 (42.7) History of high cholesterol levels
22 (5.4) 11 (4.4) 14 (7.2) 349 (6.4) Cholesterol lowering drug use
160 (39.0) 84 (33.9) 79 (40.5) 1860 (33.8) Oral contraceptive use
Postmenopausal hormone use:
143 (34.9) 84 (33.9) 48 (24.6) 2258 (41.1) Never
91 (22.2) 46 (18.6) 43 (22.1) 1055 (19.2) Past
174 (42.4) 118 (47.6) 104 (53.3) 2175 (39.6) Current
Alcohol consumption:
193 (47.1) 122 (49.2) 98 (50.3) 2611 (47.5) Rarely/never
55 (13.4) 34 (13.7) 25 (12.8) 626 (11.4) 1-3 drinks/month
110 (26.8) 76 (30.7) 50 (25.6) 1569 (28.6) 1-6 drinks/week
52 (12.7) 16(6.5) 22 (11.3) 686 (12.5) ≥1 drinks per day
Vigorous physical activity:
164 (40.0) 120 (48.4) 81 (41.5) 2369 (43.1) Rarely/never
72 (17.6) 43 (17.3) 37 (19.0) 887 (16.1) <1/week
125 (30.5) 60 (24.2) 54 (27.7) 1575 (28.7) 1-3 times/week
48 (11.7) 24 (9.7) 23 (11.8) 662 (12.1) ≥4 times/week
Smoking status:
219 (53.4) 141 (56.9) 102 (52.3) 2863 (52.1) Never
153 (37.3) 88 (35.5) 74 (38.0) 2072 (37.7) Former
38 (9.3) 18 (7.3) 19 (9.7) 556 (10.1) Current
10 (2.4) 5 (2.0) 3 (1.5) 202 (3.7) Diabetes
Highest attained education:
295 (72.0) 173 (69.8) 130 (66.7) 3598 (65.5) LPVN, associates degree, registered nurse
114 (27.8) 70 (28.2) 65 (33.3) 1810 (32.9) Bachelor’s degree or higher education
34.4 (2.6) 34.4 (2.5) 34.3 (2.6) 34.2 (2.7) Mean (SD) baseline telephone interview for
cognitive status score
9.7 (1.7) 9.6 (1.5) 9.6 (1.6) 9.6 (1.6) Mean (SD) baseline immediate EBMT
9.4 (1.7) 9.3 (1.6) 9.4 (1.7) 9.3 (1.8) Mean (SD) baseline delayed EBMT
5.0 (1.7) 4.9 (1.8) 4.9 (1.8) 4.8 (1.8) Mean (SD) baseline immediate 10 word list recall
3.1 (2.0) 3.0 (2.1) 2.9 (1.9) 3.0 (2.1) Mean (SD) baseline delayed 10 word list recall
17.8 (5.0) 18.0 (5.0) 18.2 (5.1) 17.5 (4.9) Mean (SD) baseline category fluency score
LPVN=licensed practical nurse/licensed vocational nurse; EBMT=east Boston memory test.
Numbers may not add up to 100% because of rounding or missing data.
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RESEARCHTable 2| Multivariable adjusted mean cognitive scores and standard errors at each follow-up assessment (about two years apart) by migraine
status
Overall
P value
Past history of migraine Migraine without aura Migraine with aura No history of migraine Cognitive
tests at
Adjusted
mean* (SE)
No of
participants
Adjusted
mean* (SE)
No of
participants
Adjusted
mean* (SE)
No of
participants
Adjusted
mean* (SE)
No of
participants
assessment
points
Global score†:
0.11 0.05 (0.04) 410 −0.01 (0.05) 248 0.01 (0.05) 195 −0.02 (0.03) 5496 First
0.30 0.12 (0.05) 370 0.07 (0.06) 220 0.08 (0.06) 174 0.05 (0.04) 4902 Second
0.15 0.03 (0.05) 337 0.04 (0.06) 202 0.08 (0.07) 167 −0.02 (0.04) 4496 Third
Verbal score†:
0.18 0.05 (0.05) 410 −0.03 (0.05) 248 −0.02 (0.06) 195 −0.03 (0.03) 5496 First
0.69 0.16 (0.05) 370 0.14 (0.06) 220 0.17 (0.07) 174 0.12 (0.04) 4902 Second
0.31 0.13 (0.06) 337 0.12 (0.07) 202 0.17 (0.07) 167 0.08 (0.04) 4496 Third
Telephone
interview for
cognitive
status:
0.17 34.48 (0.18) 408 34.29 (0.21) 248 34.24 (0.23) 195 34.18 (0.13) 5483 First
0.94 33.88 (0.20) 370 33.95 (0.24) 220 33.80 (0.25) 174 33.85 (0.14) 4898 Second
0.84 33.99 (0.22) 337 34.02 (0.26) 202 33.86 (0.27) 167 33.88 (0.16) 4496 Third
Category
fluency test:
0.09 17.63 (0.33) 407 17.58 (0.39) 247 17.86 (0.42) 195 17.22 (0.24) 5476 First
0.01 18.43 (0.37) 370 17.72 (0.44) 220 17.51 (0.47) 174 17.52 (0.27) 4898 Second
0.01 17.05 (0.39) 337 17.46 (0.45) 202 17.94 (0.48) 167 16.82 (0.28) 4495 Third
P values from analysis of covariance comparing no history of migraine, migraine with aura, migraine without aura, and past history of migraine.
*Adjusted for age, smoking status, alcohol consumption, body mass index, educational attainment, postmenopausal hormone use, history of high cholesterol
levels, treatment for high cholesterol levels, history of hypertension, treatment for hypertension, diabetes, and past oral contraceptive use.
†Scores measured in standardised units.
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RESEARCHTable 3| Age and multivariate adjusted associations between rate of change in cognitive function by migraine status
Category fluency score
Telephone interview for
cognitive status Verbal score* Global score*
Migraine status and
assessments P value
Coefficient
(SE) P value Coefficient (SE) P value
Coefficient
(SE) P value
Coefficient
(SE)
Age adjusted
— — — — — — — — First assessment
(reference)
<0.01 0.54 (0.07) 0.01 −0.11 (0.04) <0.01 0.13 (0.01) <0.01 0.07 (0.01) Second assessment
0.70 0.03 (0.07) 0.01 −0.12 (0.04) <0.01 0.10 (0.01) 0.06 0.02 (0.01) Third assessment
— — — — — — — — No migraine
(reference)
0.07 0.65 (0.36) 0.80 0.05 (0.19) 0.83 0.01 (0.05) 0.47 0.03 (0.04) Migraine with aura:
0.05 −0.77 (0.39) 0.58 −0.12 (0.21) 0.72 0.02 (0.05) 0.68 −0.02 (0.05) Second assessment
0.37 0.36 (0.40) 0.61 −0.11 (0.22) 0.28 0.06 (0.06) 0.29 0.05 (0.05) Third assessment
0.28 0.34 (0.32) 0.75 0.05 (0.16) 0.67 −0.02 (0.04) 0.90 0.0045 (0.04) Migraine without aura:
0.71 −0.12 (0.33) 0.64 0.09 (0.19) 0.36 0.05 (0.05) 0.48 0.03 (0.04) Second assessment
0.41 0.28 (0.34) 0.19 0.26 (0.20) 0.15 0.08 (0.05) 0.09 0.08 (0.04) Third assessment
0.16 0.35 (0.25) 0.06 0.24 (0.13) 0.047 0.07 (0.03) 0.03 0.07 (0.03) Past history of
migraine:
0.13 0.44 (0.29) 0.13 −0.24 (0.16) 0.46 −0.03 (0.04) 0.89 −0.0047 (0.03) Second assessment
0.74 −0.09 (0.27) 0.42 −0.13 (0.16) 0.72 −0.01 (0.04) 0.74 −0.01 (0.04) Third assessment
Multivariable adjusted†
— — — — — — — — First assessment
(reference)
<0.01 0.54 (0.07) 0.01 −0.11 (0.04) <0.01 0.13 (0.01) <0.01 0.07 (0.01) Second assessment
0.77 0.02 (0.07) 0.01 −0.12 (0.04) <0.01 0.09 (0.01) 0.07 0.02 (0.01) Third assessment
— — — — — — — — No migraine
(reference)
0.07 0.65 (0.36) 0.83 0.04 (0.18) 0.85 0.01 (0.05) 0.49 0.03 (0.04) Migraine with aura:
0.05 −0.77 (0.39) 0.59 −0.11 (0.21) 0.71 0.02 (0.05) 0.69 −0.02 (0.05) Second assessment
0.36 0.37 (0.40) 0.62 −0.11 (0.22) 0.28 0.06 (0.06) 0.28 0.05 (0.05) Third assessment
0.24 0.36 (0.31) 0.65 0.07 (0.16) 0.77 −0.01 (0.04) 0.75 0.01 (0.04) Migraine without aura:
0.72 −0.12 (0.33) 0.64 0.09 (0.19) 0.35 0.05 (0.05) 0.48 0.03 (0.04) Second assessment
0.41 0.28 (0.34) 0.21 0.25 (0.20) 0.15 0.08 (0.05) 0.09 0.08 (0.04) Third assessment
0.09 0.42 (0.25) 0.02 0.29 (0.13) 0.03 0.08 (0.03) 0.01 0.08 (0.03) Past history of
migraine:
0.13 0.44 (0.29) 0.13 −0.24 (0.16) 0.46 −0.03 (0.04) 0.89 −0.0047 (0.03) Second assessment
0.75 −0.09 (0.27) 0.43 −0.13 (0.16) 0.72 −0.01 (0.04) 0.75 −0.01 (0.04) Third assessment
Global score and category fluency do not control for treatment for high cholesterol levels owing to problems with model convergence. The coefficients shown are
the results of the joint effects of migraine status and the respective follow-up time.
*Measured in standardised units.
†Adjusted for age, smoking status, alcohol consumption, body mass index, educational attainment, postmenopausal hormone use, history of high cholesterol
levels, treatment for high cholesterol levels, history of hypertension, treatment for hypertension, diabetes, and past oral contraceptive use.
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RESEARCHTable 4| Multivariable adjusted* relative risk of substantial cognitive decline† by migraine status
P value
Relative risk of substantial decline (95%
CI) No of women Cognitive test and migraine status
Global score‡:
1.00 457 No history of migraine
0.64 1.09 (0.68 to 1.77) 12 Migraine with aura
0.21 0.77 (0.46 to 1.28) 15 Migraine without aura
0.29 1.17 (0.84 to 1.63) 36 Past history of migraine
Verbal score†:
1.00 458 No history of migraine
0.25 0.64 (0.34 to 1.20) 11 Migraine with aura
0.83 0.82 (0.48 to 1.38) 16 Migraine without aura
0.29 1.02 (0.71 to 1.48) 35 Past history of migraine
Telephone interview for cognitive status:
1.00 505 No history of migraine
0.38 0.70 (0.39 to 1.28) 20 Migraine with aura
0.58 0.77 (0.45 to 1.32) 17 Migraine without aura
0.26 1.05 (0.73 to 1.51) 44 Past history of migraine
Category fluency score:
1.00 423 No history of migraine
0.80 1.03 (0.61 to 1.74) 16 Migraine with aura
0.67 0.89 (0.54 to 1.48) 17 Migraine without aura
0.97 0.98 (0.67 to 1.44) 31 Past history of migraine
*Adjusted for age, smoking status, alcohol consumption, body mass index, educational attainment, postmenopausal hormone use, history of high cholesterol
levels, treatment for high cholesterol levels, history of hypertension, treatment for hypertension, diabetes, past oral contraceptive use, and time from entry into the
Women’s Health Study to last interview.
†Substantial cognitive decline was defined as the worst 10% of the distribution of decline from the initial to the final cognitive assessment of the whole study cohort.
‡Measured in standardised units.
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RESEARCHFigure
Flow chart of participation in migraine and cognitive decline study among women enrolled in the Women’s Health Study
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